The use of recombinant adeno-associated virus for skeletal gene therapy

Orthodontics and Craniofacial Research

Volumn 10, Issue 1, 2007, Pages 1-14

  Dai, Juan ^a   Rabie, A Bakr M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adeno associated virus; Cartilage; Gene therapy; Mandible; Rheumatoid arthritis; Temporomandibular joint

Indexed keywords

RECOMBINANT DNA;

ADENO ASSOCIATED VIRUS; BONE DISEASE; CHONDROPATHY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; REVIEW; RHEUMATOID ARTHRITIS; VIRUS DNA CELL DNA INTERACTION;

ARTHRITIS, RHEUMATOID; BONE DISEASES; CARTILAGE DISEASES; DEPENDOVIRUS; DNA, RECOMBINANT; GENE THERAPY; GENETIC VECTORS; HUMANS; VIRUS INTEGRATION;

EID: 34047177517     PISSN: 16016335     EISSN: 16016343     Source Type: Journal    
DOI: 10.1111/j.1601-6343.2007.00381.x     Document Type: Review

References (129)

1. Glant TT. Short overview of potential gene therapy approaches in orthopedic spine surgery. Spine 2003;28:207-8.
2. Dai J, Rabie AB, Hagg U, Xu R. Alternative gene therapy strategies for the repair of craniofacial bone defects. Curr Gene Ther 2004;4:469-85.
3. Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med 1999;5:587-8.
4. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
5. Herweijer H, Wolff JA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003;10:453-8.
6. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52.
7. Ohashi S, Kubo T, Kishida T, Ikeda T, Takahashi K, Arai Y et al. Successful genetic transduction in vivo into synovium by means of electroporation. Biochem Biophys Res Commun 2002;293:1530-5.
8. Yovandich J, O'Malley B Jr, Sikes M, Ledley FD. Gene transfer to synovial cells by intra-articular administration of plasmid DNA. Hum Gene Ther 1995;6:603-10.
9. Yovandich J, O'Malley Jr B, Sikes M, Ledley FD. Gene transfer to synovial cells by intra-articular administration of plasmid DNA. Hum Gene Ther 1995;6:603-10.
10. Grossin L, Cournil-Henrionnet C, Mir LM, Liagre B, Dumas D, Etienne S et al. Direct gene transfer into rat articular cartilage by in vivo electroporation. Faseb J 2003;17:829-35.
11. Bonadio J, Cunningham ML. Genetic approaches to craniofacial tissue repair. Ann N Y Acad Sci 2002;961:48-57.
12. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A 1984;81:6349-53.
13. Luk KD, Chen Y, Cheung KM, Kung H, Lu WW, Leong JC. Adenoassociated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo bone formation. Biochem Biophys Res Commun 2003;308:636-45.
14. Jiang ZL, Reay D, Kreppel F, Gambotto A, Feingold E, Kochanek S et al. Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol Ther 2001;3:892-900.
15. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984;81:6466-70.
16. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-32.
17. Smith-Arica JR, Thomson AJ, Ansell R, Chiorini J, Davidson B, McWhir J. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning Stem Cells 2003;5:51-62.
18. Tan M, Qing K, Zhou S, Yoder MC, Srivastava A. Adeno-associated virus 2-mediated transduction and erythroid lineagerestricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. Mol Ther 2001;3:940-6.
19. Ponnazhagan S, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J Virol 1997;71:3098-104.
20. Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum Gene Ther 2004;15:1197-206.
21. McMahon JM, Conroy S, Lyons M, Greiser U, O'Shea C, Strappe P et al. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev 2006;15:87-96.
22. Ju XD, Lou SQ, Wang WG, Peng JQ, Tian H. Effect of hydroxyurea and etoposide on transduction of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors. Acta Pharmacol Sin 2004;25:196-202.
23. Ito H, Goater JJ, Tiyapatanaputi P, Rubery PT, O'Keefe RJ, Schwarz EM. Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells. Gene Ther 2004;11:34-41.
24. Ulrich-Vinther M, Stengaard C, Schwarz EM, Goldring MB, Soballe K. Adeno-associated vector mediated gene transfer of transforming growth factor-beta1 to normal and osteoarthritic human chondrocytes stimulates cartilage anabolism. Eur Cell Mater 2005;10:40-50.
25. Arai Y, Kubo T, Fushiki S, Mazda O, Nakai H, Iwaki Y et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol 2000;27:979-82.
26. Madry H, Cucchiarini M, Terwilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther 2003;14:393-402.
27. Ulrich-Vinther M, Duch MR, Soballe K, O'Keefe RJ, Schwarz EM, Pedersen FS. In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector. J Orthop Res 2004;22:726-34.
28. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H et al. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 2004;9:587-95.
29. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 2003;311:89-95.
30. Chen M, Wang GJ, Diao Y, Xu RA, Xie HT, Li XY et al. Adenoassociated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo. World J Gastroenterol 2005;11:4045-51.
31. Smith AD, Collaco RF, Trempe JP. Enhancement of recombinant adeno-associated virus type 2-mediated transgene expression in a lung epithelial cell line by inhibition of the epidermal growth factor receptor. J Virol 2003;77:6394-404.
32. MonahanPE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000;6:433-40.
33. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996;218:1-23.
34. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996;7:507-13.
35. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998;72:7024-31.
36. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998;9:695-706.
37. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 1997;71:8780-9.
38. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996;93:14082-7.
39. Oligino TJ, Yao Q, Ghivizzani SC, Robbins P. Vector systems for gene transfer to joints. Clin Orthop 2000;379:S17-30.
40. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004;11:805-10.
41. Hermonat PL, Quirk JG, Bishop BM, Han L. The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett 1997;407:78-84.
42. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001;4:383-91.
43. Yan Z, Ritchie TC, Duan D, Engelhardt JF. Recombinant AAVmediated gene delivery using dual vector heterodimerization. Methods Enzymol 2002;346:334-57.
44. Chao H, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther 2002;5:716-22.
45. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons. Mol Med Today 2000;6:433-40.
46. Zhang X, Godbey WT. Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev 2006;58:515-34.
47. Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999;380:613-22.
48. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002;76:791-801.
49. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A 2003;100:6081-6.
50. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7:839-50.
51. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003;3:281-304.
52. Pan RY, Xiao X, Chen SL, Li J, Lin LC, Wang HJ et al. Diseaseinducible transgene expression from a recombinant adenoassociated virus vector in a rat arthritis model. J Virol 1999;73:3410-7.
53. Gao G, Alvira MR, WangL, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-9.
54. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-8.
55. Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004;330:375-83.
56. Muzyczka N, Samulski RJ, Hermonat P, Srivastava A, Berns KI. The genetics of adeno-associated virus. Adv Exp Med Biol 1984;179:151-61.
57. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-45.
58. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71-7.
59. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82.
60. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 2005;79:609-14.
61. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 4 2001; 6884-93.
62. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003;9:1306-12.
63. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003;102:2412-9.
64. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005;65:1687-92.
65. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983;45:555-64.
66. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-45.
67. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2005;2:43.
68. Lusby E, Fife KH, Berns KI. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J Virol 1980;34:402-9.
69. Merten OW, Geny-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther 2005;12(Suppl. 1): S51-61.
70. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-85.
71. Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 2002;13:1235-43.
72. Burova E, Ioffe E. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther 2005;12(Suppl. 1): S5-17.
73. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997;71:7951-9.
74. Lotery AJ, Yang GS, Mullins RF, Russell SR, Schmidt M, Stone EM et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther 2003;14:1663-71.
75. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995;2:357-62.
76. O'Riordan CR, Lachapelle AL, Vincent KA, Wadsworth SC. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med 2000;2:444-54.
77. Ostedgaard LS, Rokhlina T, Karp PH, Lashmit P, Afione S, Schmidt M et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci U S A 2005;102:2952-7.
78. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003;3:545-65.
79. Huttner NA, Girod A, Schnittger S, Schoch C, Hallek M, Buning H. Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid. J Gene Med 2003;5:120-9.
80. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 2004;10:660-70.
81. Le Bec C, Douar AM. Gene therapy progress and prospects-vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006;13:805-13.
82. McCarty DM, Young SM Jr, Samulski RJ. Integration of adenoassociated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004;38:819-45.
83. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996;70:520-32.
84. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005;5:299-310.
85. Duan D, Yue Y, Yan Z, McCray PB Jr, Engelhardt JF. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther 1998;9:2761-76.
86. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 2005;79:14793-803.
87. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005;5:323-31.
88. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adenoassociated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000;74:1761-6.
89. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-83.
90. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997;3:306-12.
91. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000;74:2420-5.
92. Toniatti C, Bujard H, Cortese R, Ciliberto G. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 2004;11:649-57.
93. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005;12:189-211.
94. Chen Y, Luk KD, Cheung KM, Xu R, Lin MC, Lu WW et al. Gene therapy fornewbone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther 2003;10:1345-53.
95. Yang M, Ma QJ, Dang GT, Ma KT, Chen P, Zhou CY. Adenoassociated virus-mediated bone morphogenetic protein-7 gene transfer induces C2C12 cell differentiation into osteoblast lineage cells. Acta Pharmacol Sin 2005;26:963-8.
96. Chen Y, Luk KD, Cheung KM, Lu WW, An XM, Ng SS et al. Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 2004;317:675-81.
97. Li JZ, Li H, Hankins GR, Lieu AS, Noh E, Jacobson L et al. Different osteogenic potentials of recombinant human BMP-6 adeno-associated virus and adenovirus in two rat strains. Tissue Eng 2006;12:209-19.
98. Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64.
99. Ulrich-Vinther M, Schwarz EM, Pedersen FS, Soballe K, Andreassen TT. Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. Bone 2005;37:751-8.
100. Ulrich-Vinther M, Carmody EE, Goater JJ, Sb K, O'Keefe RJ, Schwarz EM. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 2002; 1405-12.
101. Yang SY, Mayton L, Wu B, Goater JJ, Schwarz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002;46:2514-23.
102. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 2005;11:291-7.
103. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT et al. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 2005;12:212-8.
104. Ulrich-Vinther M, MaloneyMD, Goater JJ, Soballe K, Goldring MB, O'Keefe RJ et al. Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular chondrocytes. Arthritis Rheum 2002;46:2095-104.
105. Maloney MD, Goater JJ, Parsons R, Ito H, O'Keefe RJ, Rubery PT et al. Safety and efficacy of ultraviolet-a light-activated gene transduction for gene therapy of articular cartilage defects. J Bone Joint Surg Am 2006;88:753-61.
106. Hiraide A, Yokoo N, Xin KQ, Okuda K, Mizukami H, Ozawa K et al. Repair of articular cartilage defect by intraarticular administration of basic fibroblast growth factor gene, using adeno-associated virus vector. Human Gene Therapy 2005;16:1413-21.
107. Cucchiarini M, Madry H, Ma C, Thurn T, Zurakowski D, Menger MD et al. Improved tissue repair in articular cartilage defects in vivo by rAAV-mediated overexpression of human fibroblast growth factor 2. Mol Ther 2005;12:229-38.
108. Kuboki T, Nakanishi T, Kanyama M, Sonoyama W, Fujisawa T, Kobayashi K, et al. Direct adenovirus-mediated gene delivery to the temporomandibular joint in guinea-pigs. Arch Oral Biol 1999;44:701-9.
109. Kyrkanides S, Kambylafkas P, Miller JH, Tallents RH. Non-primate lentiviral vector administration in the TMJ. J Dent Res 2004;83:65-70.
110. Watanabe S, Imagawa T, Boivin GP, Gao G, Wilson JM, Hirsch R. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2000;2:147-52.
111. Goater J, Muller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J. Rheumatol. 2000;27:983-9.
112. Pan RY, Chen SL, Xiao X, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000;43:289-97.
113. Kobayashi N, Koshino T, Uesugi M, Yokoo N, Xin KQ, Okuda K et al. Gene marking in adeno-associated virus vector infected periosteum derived cells for cartilage repair. J Rheumatol 2002;29:2176-80.
114. Yokoo N, Saito T, Uesugi M, Kobayashi N, Xin KQ, Okuda K et al. Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector. Arthritis Rheum 2005;52:164-70.
115. Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther 2005;11:600-7.
116. Watanabe S, Kim KN, Imagawa T, Thornton S, Grom A, Hirsch R. On the mechanism of protection of distal joints after local gene transfer in collagen-induced arthritis. Hum Gene Ther 2000;11:751-8.
117. Zhang HG, Xie J, Yang P, Wang Y, Xu L, Liu D et al. Adenoassociated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther 2000;11:2431-42.
118. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 2000;7:1930-9.
119. Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002;13:1179-88.
120. Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002;6:727-36.
121. Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 2005;23:455-61.
122. Apparailly F, Khoury M, Vervoordeldonk MJ, Adriaansen J, Gicquel E, Perez N et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther 2005;16:426-34.
123. Tas SW, Adriaansen J, Hajji N, Bakker AC, Firestein GS, Vervoordeldonk MJ et al. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adenoassociated virus type 5. Hum Gene Ther 2006;17:821-32.
124. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989;339:27-30.
125. Gafni Y, Turgeman G, Liebergal M, Pelled G, Gazit Z, Gazit D. Stem cells as vehicles for orthopedic gene therapy. Gene Ther 2004;11:417-26.
126. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004;303:1198-201.
127. Rabie AB, Hagg U. Factors regulating mandibular condylar growth. Am J Orthod Dentofacial Orthop 2002;122:401-9.
128. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P et al. Clinical protocol. Administration of a replicationdeficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004;15:1131-54.
129. Dai J, Rabie AB. Direct AAV-mediated gene delivery to the temporomandibular joint. Front Biosci 2007;12:2212-20.